Log in

Cleveland BioLabs Stock Price, News & Analysis (NASDAQ:CBLI)

-0.09 (-10.23 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: $0.79
50-Day Range
MA: $1.09
52-Week Range
Now: $0.79
Volume27,980 shs
Average Volume25,991 shs
Market Capitalization$8.93 million
P/E RatioN/A
Dividend YieldN/A
Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:CBLI



Sales & Book Value

Annual Sales$1.14 million
Book Value$0.32 per share


Net Income$-3,610,000.00
Net Margins-304.43%


Market Cap$8.93 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. The biotechnology company earned $0.28 million during the quarter. Cleveland BioLabs had a negative net margin of 304.43% and a negative return on equity of 96.01%. View Cleveland BioLabs' Earnings History.

When is Cleveland BioLabs' next earnings date?

Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Cleveland BioLabs.

Has Cleveland BioLabs been receiving favorable news coverage?

News coverage about CBLI stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cleveland BioLabs earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cleveland BioLabs.

Are investors shorting Cleveland BioLabs?

Cleveland BioLabs saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 27,400 shares, an increase of 25.1% from the August 30th total of 21,900 shares. Based on an average daily trading volume, of 9,000 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.6% of the shares of the company are sold short. View Cleveland BioLabs' Current Options Chain.

Who are some of Cleveland BioLabs' key competitors?

What other stocks do shareholders of Cleveland BioLabs own?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:
  • Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)
  • Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)
  • Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
  • Dr. Andrei Purmal Ph.D., VP of Chemistry

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $0.79.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $8.93 million and generates $1.14 million in revenue each year. View Additional Information About Cleveland BioLabs.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is http://www.cbiolabs.com/.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel